Invesco Ltd. Has $1.67 Million Stock Holdings in 10x Genomics $TXG

Key Points

• Invesco Ltd. increased its stake in 10x Genomics by 62.1%, acquiring an additional 73,265 shares, bringing its total to 191,332 shares, valued at approximately $1.67 million.
• Several institutional investors have also adjusted their holdings, with major purchases including First Trust Advisors LP increasing its stake by 159.9% in the fourth quarter.
• 10x Genomics reported a significant quarterly earnings beat, earning $0.28 per share against an expected loss of $0.35, with revenue reaching $172.91 million, exceeding analyst forecasts of $139.36 million.

Invesco Ltd. lifted its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 62.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 191,332 shares of the company's stock after buying an additional 73,265 shares during the quarter. Invesco Ltd. owned approximately 0.16% of 10x Genomics worth $1,670,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in shares of 10x Genomics during the 4th quarter worth $32,000. GAMMA Investing LLC raised its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the last quarter. Signaturefd LLC raised its stake in shares of 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after buying an additional 2,409 shares during the last quarter. Whittier Trust Co. acquired a new position in shares of 10x Genomics during the 1st quarter worth $41,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after buying an additional 3,119 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Trading Up 0.5%

TXG stock traded up $0.07 on Thursday, hitting $13.41. 560,600 shares of the company's stock traded hands, compared to its average volume of 3,352,610. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.38. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -19.14 and a beta of 2.00. The stock has a fifty day moving average of $13.07 and a 200-day moving average of $10.73.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. During the same period in the prior year, the business earned ($0.32) earnings per share. The business's quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TXG has been the subject of several research reports. Barclays reaffirmed an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. UBS Group boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Finally, Bank of America boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $13.54.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock valued at $539,865 over the last ninety days. Insiders own 10.03% of the company's stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.